Harrow Health Inc. 8.625%... (HROWL)
25.11
0.20 (0.80%)
At close: Jan 15, 2025, 11:04 AM
Company Description
Harrow, Inc. engages in the development, production, and sale of innovative medications.
It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.
The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business.
The company was founded by Mark L.
Baum and Robert J.
Kammer in January 2006 and is headquartered in Nashville, TN.
Harrow Health Inc. 8.625% Senior Notes due 2026
| Country | United States |
| IPO Date | May 7, 2021 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Mark L. Baum |
Contact Details
Address: No Address available Nashville, United States | |
| Website | http://www.harrowinc.com |
Stock Details
| Ticker Symbol | HROWL |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001360214 |
| CUSIP Number | n/a |
| ISIN Number | US4158582084 |
| Employer ID | 45-0567010 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | 4 | Filing |
| Jan 08, 2025 | 3 | Filing |
| Dec 05, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 13, 2024 | 4 | Filing |
| Sep 09, 2024 | 8-K | Current Report |
| Aug 07, 2024 | 10-Q | Quarterly Report |